Answers are grounded in this paper and cite their sources.
For expensive specialty drugs, it’s unclear how quickly substantial price competition among generics manufacturers can be achieved. Even if generic specialty drugs have far lower list prices than brand-name versions, savings may not accrue to Medicare beneficiaries.
No takes yet. Share an insight, caveat, or question.
Dusetzina et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: